We are live on ! Find out more
IKT icon

Inhibikase Therapeutics
IKT

21 hedge funds and large institutions have $7.78M invested in Inhibikase Therapeutics in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

50% more funds holding

Funds holding: 14 → 21 (+7)

0.2% more ownership

Funds ownership: 2.52% → 2.72% (+0.2%)

27% less capital invested

Capital invested by funds: $10.6M → $7.78M (-$2.84M)

Holders
21
Holders Change
+7
Holders Change %
+50%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
6
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
ACT Capital Management
Pennsylvania
+$304K
2
Millennium Management
Millennium Management
New York
+$228K
3
AC
Antara Capital
New York
+$119K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$89.2K
5
BlackRock
BlackRock
New York
+$83.8K

Top Sellers

Rank Fund Capital Flow
1
ACM
Altium Capital Management
New York
-$307K
2
WAM
Warberg Asset Management
Illinois
-$144K
3
HF
HRT Financial
New York
-$42K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
ACT Capital Management
Pennsylvania
$1.92M +$304K +22,500 +15%
KC
2
Kepos Capital
New York
$1.33M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$909K +$18.2K +1,348 +2%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$823K – – –
SM
5
Sabby Management
Florida
$808K +$8.6K +636 +0.9%
M
6
Murchinson
Ontario, Canada
$610K – – –
AC
7
Antara Capital
New York
$576K +$119K +8,833 +21%
Millennium Management
8
Millennium Management
New York
$192K +$228K +16,880 New
ZCA
9
Zeke Capital Advisors
Pennsylvania
$178K – – –
BlackRock
10
BlackRock
New York
$96K +$83.8K +6,195 +274%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$75K +$89.2K +6,597 New
Goldman Sachs
12
Goldman Sachs
New York
$53K +$62.9K +4,649 New
WAM
13
Warberg Asset Management
Illinois
$49K -$144K -10,667 -71%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$49K +$58.2K +4,306 New
SC
15
Shay Capital
New York
$38K +$45.1K +3,333 New
Northern Trust
16
Northern Trust
Illinois
$30K +$35.4K +2,619 New
Envestnet Asset Management
17
Envestnet Asset Management
Illinois
$21K +$24.8K +1,831 New
UBS Group
18
UBS Group
Switzerland
$16K +$19.3K +1,425 New
TRCT
19
Tower Research Capital (TRC)
New York
$10K +$12.2K +901 New
Rockefeller Capital Management
20
Rockefeller Capital Management
New York
$2K – – –
ACM
21
Altium Capital Management
New York
– -$307K -18,292 Closed
HF
22
HRT Financial
New York
– -$42K -2,500 Closed
Wells Fargo
23
Wells Fargo
California
– +$243 +18 +900%

IKT Hedge Fund Activity: Q3 2021 in Review

21 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q3 2021, worth a combined $7.78M — down 27% from $10.6M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new IKT positions and 2 closed out — a net gain of 7 holders — while 6 added to existing stakes and 1 trimmed.

The largest buyer was ACT Capital Management, adding an estimated $304K. The largest seller was Altium Capital Management, exiting entirely with an estimated $307K sold.

  • 21 institutional investors held Inhibikase Therapeutics (IKT) as of Q3 2021, up from 14 in Q2 2021.
  • Funds reported $7.78M of Inhibikase Therapeutics stock for Q3 2021, down 27% quarter-over-quarter.
  • 9 funds opened new Inhibikase Therapeutics positions in Q3 2021 and 2 closed out, a net change of +7 holders.
  • The largest Inhibikase Therapeutics buyer in Q3 2021 was ACT Capital Management, an estimated $304K added.
  • The largest Inhibikase Therapeutics seller in Q3 2021 was Altium Capital Management, an estimated $307K sold.

Based on aggregated 13F filings for Q3 2021.